- Details
- (Length of Interview: 16 min) Charles Ryan, MD interviews Mark Scholz, MD, a medical oncologist in Marina del Rey, CA about his newest book The Key to Prostate Cancer: 30 Experts Explain 15 Stages of Prostate Cancer . This book equips patients with the understanding of where they stand in the spectrum of prostate cancer in terms of the different stages of the disease. The Key to Prostate Cancer: 3...
|
- Details
- (Length of Discussion: 23 min) Petros Grivas and Alicia Morgans talk post-ASCO 2018 about a number of studies and abstracts presented. The first they review is the ABACUS study presented by Thomas Powles, MD. This single arm, phase II study investigated two cycles of atezolizumab (1200mg every three weeks) prior to radical cystectomy among patients with T2-4N0M0 urothelial carcinoma. The second st...
|
- Details
- (Length of Discussion: 16 min) Petros Grivas and Alicia Morgans discuss the late-breaking FDA Alert announcing the label changes for Pembrolizumab and Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1. Biographies: Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate c...
|
- Details
- (Length of Presentation: 5 min) Benjamin Brucker, MD details Clinical Evaluation and Treatment of Nocturia is Modest at Best a 2018 AUA meeting presentation by Siri Drangsholt, MD, of the New York University School of Medicine. A retrospective chart review was performed to select patients who had a primary complaint of nocturia. Patients who presented with a new patient encounter were entered into...
|
- Details
- (Length of Presentation: 11 min) Benjamin Brucker, MD presents his 2018 AUA presentation Extended First Uninterrupted Sleep Period in Elderly Patients Following Treatment with AV002, an Emulsified Low Dose Vasopressin Analog for Nocturia in a detailed video lecture. A brief review of the short-term and long-term negative consequences of nocturia highlights the relevance of this trial. The objectiv...
|
- Details
- (Length of Discussion: 19 min) Benjamin Brucker, MD interviews Jeffrey Weiss, MD on the prevalence and demographics of the nocturia patient and when nocturia becomes problematic. Weiss highlights the quality of life versus profound health concerns, in terms of epidemiology and severe nocturia. He explains where early mortality fits in and the side effects patients are more prone to, including fall...
|
- Details
- (Length of conversation: 14 minutes) Alicia Morgans and Arjun Balar converse on the long-term efficacy data of atezolizumab in the 1st line setting as well as the 2nd line setting from the single-arm phase 2 trial. Discussion evolves to the recent safety alerts by the FDA highlighting the two studies, Keynote 361 and IMvigor 130. They question the applicability to clinical practice and the challen...
|
- Details
- (Length of Discussion: 10 min) Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease. They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease. In discussing the best w...
|
- Details
- (Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...
|
- Details
- (Lenght of Discussion: 14 min) Tom Keane reviews three key presentations from the most recent American Urological Association (AUA) 2018 meeting. Among the presentations Keane discusses is a prostate cancer Imaging presentation by the Chief of MRI and Nuclear Medicine at the San Francisco VA Medical Center, Thomas Hope, MD. During his presentation, Prostate Cancer: What PET to GET? Hope discussed...
|
